Kymera says Sanofi to advance KT-485 into clinical testing

Kymera Therapeutics (KYMR) announced an update to its IRAK4 partnership with Sanofi (SNY). Sanofi has informed Kymera that KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases that Kymera has discovered and characterized through preclinical studies, has been selected to advance into clinical studies. Following extensive preclinical work supporting its robust development potential, KT-485 is being prioritized for development under the companies’ existing IRAK4 collaboration, and is expected to advance into Phase 1 testing next year. Based on the planned development of KT-485, Sanofi will not advance KT-474. In conjunction with its plans to advance KT-485, Sanofi also communicated its decision to exercise its participation election right for the IRAK4 target under the terms of the companies’ collaboration agreement. Under the agreement, Kymera achieved a $20M milestone in the second quarter of 2025 related to preclinical activities associated with KT-485. Kymera is eligible to receive up to $975M of potential clinical, regulatory and commercial milestones related to KT-485, including an additional milestone upon the start of Phase 1 clinical testing.